Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

Abstract: An object of this invention is to provide a single-crystal nickel-based superalloy having high creep rupture strength at high temperatures and excel at corrosion resistance and oxidation resistance at high temperatures. Single-crystal nickel-based superalloys with high temperature strength, hot corrosion resistance and oxidation resistance comprising by weight, 3.0 to 7.0% Cr, 9.5 to 15.0% Co, 4.5 to 8.0% W, 3.3 to 6.0% Re, 4.0 to 8.0% Ta, 0.8 to 2.0% Ti, 4.5 to 6.5% Al, 0.01 to 0.2% Hf, less than 0.5% Mo, 0.01% or less C, 0.005% or less B, 0.01% or less Zr, 0.005% or less O, 0.005% or less N, and balance substantially Ni.

Abstract: Nickel based superalloys with excellent mechanical strength, corrosion resistance and oxidation resistance, which consist essentially of chromium in an amount of 3 to 7% by weight, cobalt in an amount of 3 to 15% by weight, tungsten in an amount of 4.5 to 8% by weight, rhenium in an amount of 3.3 to 6% by weight, tantalum in an amount of 4 to 8% by weight, titanium in an amount of 0.8 to 2% by weight, aluminum in an amount of 4.5 to 6.5% by weight, ruthenium in an amount of 0.1 to 6%, hafnium in an amount of 0.01 to 0.2% by weight, molybdenum in an amount of less than 0.5% by weight, carbon in an amount 0.06% by weight or less, boron in an amount of 0.01% by weight or less, zirconium in an amount of 0.01% by weight or less, oxygen in an amount of 0.005% by weight or less, nitrogen in an amount of 0.005% by weight or less and inevitable impurities and the balance being nickel.

Abstract: A facsimile machine receives image data from a facsimile machine of another end. A Random Access Memory (RAM) stores a measured average value and fluctuation of an Eye Quality Monitor (EQM) value of the image data, and a number of error lines of the image data as an EQM data table. In past facsimile communication, a main control unit receives a training signal from the facsimile machine of the other end, and executes a training process. The main control unit measures an average value and fluctuation of an EQM value of the training signal, and compares the measured average value and the fluctuation of the EQM value with the average value and the fluctuation of the EQM value stored in the EQM data table. When there is no match, the main control unit executes the training process again.

Abstract: A user uses a control panel (13) to specify quick memory transmission and instruct the machine to begin the procedure. The first page of the document is scanned in by a scanning unit (14) and stored in a image memory (19). Upon storing of the image of the first page of the document in the image memory (19), NCU (17) automatically dials a transmission recipient. Additionally, a monitoring unit (16) allows the user to hear the sounds of the communication signals at the start of transmission. If, during the scanning of a second, third, or later page of a multi-page document, free space in the image memory (19) falls below a given value, then the page at which the memory became full is indicated to the user, thereby indicating the page at which retransmission should begin.

Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

Abstract: A communication terminal device (F) having an error correction function defined in ITU-T Recommendations T.30. The communication terminal device includes a modem (3) that can transmit data to a remote device in accordance with a plurality of modulation methods and communication speeds. A controller (1) associated with the terminal device (F) changes a current modulation method of the modem (3) to a different modulation method when an all-frame-error is detected predetermined times during data transmission. The controller (1), however, maintains the current modulation method and reduces a communication speed when a frame error other than the all-frame-error is detected prescribed times.

Abstract: An object of this invention is to provide a single-crystal nickel-based superalloy having high creep rupture strength at high temperatures and excel at corrosion resistance and oxidation resistance at high temperatures. Single-crystal nickel-based superalloys with high temperature strength, hot corrosion resistance and oxidation resistance comprising by weight, 3.0 to 7.0% Cr, 9.5 to 15.0% Co, 4.5 to 8.0% W, 3.3 to 6.0% Re, 4.0 to 8.0% Ta, 0.8 to 2.0% Ti, 4.5 to 6.5% Al, 0.01 to 0.2% Hf, less than 0.5% Mo, 0.01% or less C, 0.005% or less B, 0.01% or less Zr, 0.005% or less O, 0.005% or less N, and balance substantially Ni.

Abstract: This invention provides a compound of the following formula: 1

Abstract: A leaf of printed matter has a metachromatic image 2 printed with an ink thermally changing its color and a non-metachromatic image 3 of a colorant not changing its color. A principal figure 5 is formed of the colorant, and a background 6 is formed with the metachromatic ink. The printed matter 1 may be used to transfer its images to a cup 10. The ink of the background scene 6 in the outer layer will turn to colorless within a prescribed range of temperatures, rendering visible only the central principal figure 5. At lower temperatures, the metachromatic ink will restore its color to cause the background for instance a snowy scene to appear, thus affording a novel and fantastic visual effect.

Abstract: This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X1 and X2 are independently selected from halo, C1-C4 alkyl, hydroxy, C1-C4 alkoxy, amino, C1-C4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C1-C4 alkyl)thio, (C1-C4 alkyl)sulfinyl, (C1-C4 alkyl)sulfonyl, aminosulfonyl, or the like; R1 is selected from hydrogen, straight or branched C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, phenyl, heteroaryl and the like; R2 and R3 are independently selected from hydrogen, halo, C1-C4 alkyl, phenyl and the like; or R1 and R2 can form, together with the carbon atom to which they are attached, a C5-C7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.

Abstract: In the thermal power system, the electricity production efficiency may be improved by providing turbine members having the improved high temperature characteristic over the corresponding prior art turbine members. Turbine members may be provided by using high resistant steels composed of any one or ones selected from the group consisting of the components, including 0.08 to 0.13% of carbon (C), 8.5 to 9.8% of chromium (Cr), 0 to 1.5% of molybdenum (Mo), 0.10 to 0.25% of vanadium (V), 0.03 to 0.08% of niobium (Nb), 0.2 to 5.0% of tungsten (W), 1.5 to 6.0% of cobalt (Co), 0.002 to 0.015% of boron (B), 0.015 to 0.025% of nitrogen (N), and optionally, 0.01 to 3.0% of rhenium (Re), 0.1 to 0.50% of silicon (Si), 0.1 to 1.0% of manganese (Mo), 0.05 to 0.8% of nickel (Ni) and 0.1 to 1.3% of cupper.

Abstract: A facsimile apparatus (device) having a plurality of lines connected thereto and which is capable of make facsimile communication in the parallel use of these lines. More specifically, when a plurality set of data is being received through two or more lines in parallel, the facsimile device of the present invention allows the set of data that has completed storage of its first one page content most quickly to preferentially use a printer. Then that set of data is allowed to continue delivering the hard copy of whole pages and releases the printer after completing the delivery. The image data of the other set of data that was not able to occupy the printer is stored in the memory and printed out after the release of the printer. As each entire page of a set of data is successively output, image data of other sets of data is never mixed with the currently output one.

Abstract: This invention provides a compound of the following formula: 1

Abstract: A communication terminal device transmits an ANSam signal (step S2). When the device does not detect a CM signal within a prescribed period (NO in step S3 and YES in step S4), the device transmits a DIS signal with a bit indicating that the communication procedure of the V.8 mode can be carried out (step S5). Then, when receiving a CI signal (YES in step S6), the device transmits an ANSam signal (step S21 in FIG. 3), and afterwards if a CM signal cannot be detected (NO in step 22), and the number of detected CI signals is a prescribed number or more (YES in step S25), the device transmits a DIS signal without a bit indicating that the communication procedure in accordance with V.8 mode can be carried out (step S26).

Abstract: The present invention provides a compound of the formula: and its pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5 and m are as defined in claim 1. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokines mediated diseases and/or cell adhesion molecules (CAMs) mediated diseases and pharmaceutical compositions for use in such therapy.

Abstract: The present invention provides a compound of the formula: 1

Abstract: This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X1 and X2 are independently selected from halo, C1-C4 alkyl, hydroxy, C1-C4 alkoxy, amino, C1-C4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C1-C4 alkyl)thio, (C1-C4 alkyl)sulfinyl, (C1-C4 alkyl)sulfonyl, aminosulfonyl, or the like; R1 is selected from hydrogen, straight or branched C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, phenyl , heteroaryl and the like; R2 and R3 are independently selected from hydrogen, halo, C1-C4 alkyl, phenyl and the like; or R1 and R2 can form, together with the carbon atom to which they are attached, a C5-C7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.